Gilead Sciences, Inc.
GILDNext catalyst
Lenacapavir
HIV pre-exposure prophylaxis (PrEP)
Get an email about GILD's next catalysts
Track Gilead Sciences (GILD) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 20 more upcoming events in our data (Phase 2 readout, partnership, Phase 3 readout).See the timeline
21 upcoming, 3 past
Sacituzumab Govitecan (SG) Phase 2 Est. Readout
Estimated primary completion for Sacituzumab Govitecan (SG) trial (NCT06682728) in Urothelial Carcinoma. Topline data typically follows completion by weeks to months.
SourceZimberelimab Phase 2 Est. Readout
Estimated primary completion for Zimberelimab trial (NCT06048133) in Biliary Tract Carcinoma. Topline data typically follows completion by weeks to months.
SourceRemdesivir (RDV) Phase 2 Est. Readout (COVIDKIDNEY)
Estimated primary completion for Remdesivir (RDV) trial (NCT07197164) in COVID - 19. Topline data typically follows completion by weeks to months.
SourceSacituzumab Govitecan Phase 2 Est. Readout
Estimated primary completion for Sacituzumab Govitecan trial (NCT05675579) in Breast Cancer. Topline data typically follows completion by weeks to months.
SourcePartnership - Gamgertamig
Galapagos and Gilead announced a partnership on Gamgertamig with Galapagos receiving $500M in upfront cash, with registrational trials anticipated in 2027.
Sacituzumab Govitecan Phase 3 Est. Readout
Estimated primary completion for Sacituzumab Govitecan trial (NCT05609968) in Carcinoma, Non-Small-Cell Lung. Topline data typically follows completion by weeks to months.
SourceTilpisertib Fosmecarbil Phase 2 Est. Readout (PALEKONA)
Primary completion for Tilpisertib Fosmecarbil trial (NCT06029972) in Ulcerative Colitis
SourceAnti-OX40 Antibody PF-04518600 Phase 2 Est. Readout (InCITe)
Estimated primary completion for Anti-OX40 Antibody PF-04518600 trial (NCT03971409) in Stage III Breast Cancer. Topline data typically follows completion by weeks to months.
SourceUpcoming FDA decisions
Market Overview
Stock performance and key metrics
Gilead Sciences, Inc. (/ˈɡɪliəd/) is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19. It also develops medicines in therapeutic areas such as oncology and inflammation and cell therapy.
WebsiteTrodelvy
Sacituzumab Govitecan
Triple-Negative Breast Cancer
MTX
Rheumatoid Arthritis
Sustiva (Efavirenz)
HIV Infections
abacavir + didanosine + lopinavir/ritonavir (WHO recommended second line)
HIV
Epivir (Lamivudine)
HIV Infections
Antiretroviral medications
HIV Infections
Antiretroviral medications+Isoniazid prophylaxis
HIV Infections
TAF/FTC/fixed-dose combination
HIV/AIDS
B/F/TAF (TOS)
HIV-1 Infection
B/F/TAF (Low Dose)
HIV-1 Infection
Zimberelimab
Head and Neck Squamous Cell Carcinoma
Stribild
Acquired Immunodeficiency Syndrome
Sacituzumab Govitecan (SG)
Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Baseline DRV- containing ARV regimen
HIV-1
RTV
Acquired Immunodeficiency Syndrome
Seladelpar
Primary Biliary Cholangitis
Current failing ARV regimen
HIV
Adefovir Dipivoxil (ADV)
Chronic Hepatitis B
ABC/DTG/3TC
HIV-1 Infection
Axicabtagene Ciloleucel
High-risk Large B-cell Lymphoma (LBCL)
ABC/3TC
HIV-1 Infection
Elvitegravir
HIV Infection
nebulised liposomal amphotericin B
Aspergillosis
GS-4182
HIV-1-Infection
F/R/TAF
HIV-1 Infection
Stable Baseline Regimen
HIV-1-infection
Remdesivir
COVID-19
Zidovudine
HIV Infections
Adefovir Dipivoxil for
Chronic Hepatitis B
Platinum-containing Salvage Chemotherapy
Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Tobramycin inhalation solution
Cystic Fibrosis
Lenacapavir Tablet
HIV Pre-exposure Prophylaxis
F/TAF
HIV-1 Infection
EVG/COBI/FTC/TDF
Acquired Immunodeficiency Syndrome
EFV/FTC/TDF
HIV
Subcutaneous Lenacapavir
HIV-1-infection
NRTIs
HIV-1 Infection
TAF
HBeAg-positive Chronic Hepatitis B
Background regimen
HIV Infection
RBV
Hepatitis C Virus Infection
Atripla
HIV
Lepetegravir/Lenacapavir pacfosacil FDC
HIV-1-Infection
GS-3242 Injection
HIV-1-infection
COBI
Acquired Immunodeficiency Syndrome
Lepetegravir
HIV-1-Infection
Lenacapavir pacfosacil
HIV-1-Infection
Adenosine
Coronary Artery Disease
Tenofovir disoproxil fumarate
Chronic Hepatitis B
Boosted PIs
HIV-1
Tobramycin Inhalation Solution (TIS)
Cystic Fibrosis
PEGASYS (Interféron pégylé alpha -2a)
Hepatitis B
PTM B/F/TAF
HIV-1-infection
B/F/TAF (Adult Strength)
HIV-1 Infection
FTC/RPV/TDF
HIV-1 Infection
E/C/F/TAF
HIV
Tenofovir disoproxil fumarate (TDF)
Hepatitis B Virus (HBV)
Teropavimab
HIV Infection
SOF
Hepatitis C
BIC/LEN FDC
HIV-1-infection
FTC/TDF
Chronic Hepatitis B
Oral Lenacapavir
HIV-1-infection
Ranolazine
Type 2 Diabetes Mellitus
AZLI
Cystic Fibrosis
Tenofovir DF
HIV Infections
B/F/TAF
HIV-1-infection
F/TDF
Pre-Exposure Prophylaxis of HIV-1 Infection
MBX-102
Type 2 Diabetes
Filgotinib
Ulcerative Colitis
Aztreonam for Inhalation Solution (AZLI)
Cystic Fibrosis
Idelalisib
Hodgkin Lymphoma
SOF/VEL
Hepatitis C Virus Infection
Sacituzumab govitecan-hziy (SG)
Triple Negative Breast Cancer
Peg-IFN
Hepatitis C
Sacituzumab Govitecan-hziy
Triple Negative Breast Cancer
DRV/co
HIV-1 Infection
SBR
HIV-1-infection
csDMARDs
Rheumatoid Arthritis
ADV
Chronic Hepatitis B
Zinlirvimab
HIV-1-infection
Lenacapavir Injection
Pre-Exposure Prophylaxis of HIV Infection
Tenofovir Alafenamide
Chronic Hepatitis B
AmBisome
Invasive Aspergillosis
DTG
HIV-1/HBV Co-Infection
Anitocabtagene Autoleucel
Multiple Myeloma
Liposomal amphotericin B
Invasive Fungal Disease
ATV/co
HIV-1 Infection
Andecaliximab
Gastric Adenocarcinoma
Domvanalimab
Advanced Non-Small Cell Lung Cancer
Eribulin
Metastatic Breast Cancer
E/C/F/TDF
HIV
PI
HIV-1 Infection
TDF
Chronic Hepatitis B
LDV/SOF
Chronic Hepatitis C Virus
ambrisentan
Pulmonary Hypertension
Optimized Background Regimen (OBR)
HIV-1-infection
Eribulin Mesylate Injection
Metastatic Breast Cancer
Viread (tenofovir disoproxil fumarate)
HIV Infections
KITE-753
Relapsed or Refractory Large B-cell Lymphoma
GS-1720
HIV-1-infection
AZLI two times
Cystic Fibrosis
Cobicistat
Acquired Immune Deficiency Syndrome (AIDS)
SOF/VEL/VOX
Hepatitis C Virus Infection
NNRTI
Acquired Immunodeficiency Syndrome
Obeldesivir
COVID-19
PEG
Hepatitis C
Bictegravir
HIV-1-infection
Sofosbuvir
Hepatitis C, Chronic
E/C/F/TAF (Low Dose)
Acquired Immune Deficiency Syndrome (AIDS)
ISL/LEN
HIV-1-Infection
Biktarvy
Human Immunodeficiency Virus
Ledipasvir/Sofosbuvir
Hepatitis C, Chronic
Bulevirtide
Chronic Hepatitis Delta
Darusentan
Hypertension
FTC
Chronic Hepatitis B
3rd ARV agent
HIV-1
Emtricitabine (FTC)
HIV Infections
DRV
HIV-1 Infection
AZLI three times
Cystic Fibrosis
Regadenoson
Coronary Artery Disease
ATV
HIV
FTC/RPV/TAF
HIV-1 Infection
Vinflunine
Locally Advanced or Metastatic Unresectable Urothelial Cancer
3TC
HIV-1 Infection
zidovudine and lamivudine (Combivir®)
HIV Infections
Subcutaneous (SC) Lenacapavir (LEN)
Pre-Exposure Prophylaxis of HIV Infection
Failing ARV Regimen
HIV-1-infection
F/TAF (for US participants only)
Pre-Exposure Prophylaxis of HIV Infection
LPV/r
Acquired Immune Deficiency Syndrome (AIDS)
Oral Lenacapavir (LEN)
Pre-Exposure Prophylaxis of HIV Infection
Sub-cutaneous (SC) Lenacapavir (LEN)
Pre-Exposure Prophylaxis of HIV Infection
Third Unboosted Drug
Acquired Immune Deficiency Syndrome (AIDS)
Cobicistat TOS
Acquired Immune Deficiency Syndrome (AIDS)
F/TAF TOS
Acquired Immune Deficiency Syndrome (AIDS)
PTM F/TDF
Pre-Exposure Prophylaxis of HIV Infection
Ledipasvir-Sofosbuvir
Human Immunodeficiency Virus
PTM Oral LEN
Pre-Exposure Prophylaxis of HIV Infection
co-formulated TAF/FTC
HIV Infections
NRTI
Acquired Immunodeficiency Syndrome
GS-3242 Tablet
HIV-1-infection
Descovy or Truvada
HIV Infections
Harvoni
Hepatitis C
Tenofovir (TDF)
HIV Infection
emtricitabine and tenofovir DF
HIV Infections
raltegravir; maraviroc; darunavir; ritonavir; tenofovir/emtricitabine
HIV-1 Infections
enfuvirtide
HIV Infections
Sacituzumab Govitecan
Breast Cancer
Genvoya
HIV Risk
PTM ISL/LEN
HIV-1-infection
Single dose liposomal Amphotericin and Fluconazole
Cryptococcal Meningitis
Emtricitabine/tenofovir disoproxil fumarate
HIV Infection
Truvada
HIV Infections
Symtuza
HIV/AIDS
Aviptadil
Covid19
Bictegravir/Lenacapavir (BIC/LEN) FDC
HIV-1-infection
Corticosteroid
Covid19
Amrubicin (Japan only)
Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Bictegravir/Lenacapavir
HIV-1-infection
Deferred Intervention Arm
HIV Prevention
Lurbinectedin (regions/countries where approved and available)
Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Immediate Intervention Arm
HIV Prevention
Darunavir
HIV Infection
Efavirenz (EFV)
HIV Infections
FTC/TDF/EFV
HIV Infections
Rilpivirine/Emtricitabine/Tenofovir
HIV
Atazanavir
HIV Infection
Lenacapavir
HIV Prevention
Magrolimab
Myelodysplastic Syndrome
didanosine, ddI (drug)
HIV Infections
efavirenz (drug)
HIV Infections
Cabotegravir Oral Tablet
HIV Infections
CAB LA
HIV Infections
Tenofovir Disoproxil Fumarate + Emtricitabine
HIV Infections
TDF/FTC tablets
HIV Infections
emtricitabine/tenofovir + lopinavir/ritonavir (WHO recommended second line)
HIV
emtricitabine/tenofovir + darunavir + ritonavir (Second line strategy under evaluation)
HIV
FIR
Nonalcoholic Steatohepatitis
Adefovir Dipivoxil
Hepatitis B
ISL
HIV-1 Infection
GS-9451
Hepatitis C, Chronic
KTE-C19
Refractory Diffuse Large B Cell Lymphoma
brexucabtagene autoleucel
Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia
emtricitabine/tenofovir alafenamide
Acceptability of Health Care
Quemliclustat
Biliary Tract Carcinoma
Emtricitabine/tenofovir disoproxil fumarate (FTC/TDF)
Chronic Hepatitis B
SIM
Non-Alcoholic Steatohepatitis (NASH)
Esmolol
Atrial Fibrillation
GS-9451 tablet
Chronic Genotype 1a or 1b HCV Infection
MVA.HTI
HIV/AIDS
Sacituzumab Govitecan-Hziy plus bevacizumab
NSCLC Stage IV
Levocarnitine
HIV Infections
ChAdOx1.HTI
HIV/AIDS
GS-9620
HIV/AIDS
Aztreonam for Inhalation (AI)
Cystic Fibrosis
Tilpisertib Fosmecarbil
Ulcerative Colitis
Therapeutic Hydrocortisone
Non-hodgkin Lymphoma
Etrumadenant
Metastatic Colorectal Cancer
Dronedarone
Atrial Fibrillation
Axi-cel
B Cell Lymphoma
MBX-2982
Diabetes
Other approved antivirals
Chronic Hepatitis B
Firsocostat
Nonalcoholic Steatohepatitis (NASH)
PTM CILO/FIR
Nonalcoholic Steatohepatitis
PTM SEMA
Nonalcoholic Steatohepatitis
ZDV/3TC
Hepatitis C
RAL
Hepatitis C
Levetiracetam
Refractory Diffuse Large B Cell Lymphoma (DLBCL)
Peginterferon Alfa 2a
HCV Infection
TUB-040
Ovarian Cancer
LDV
Chronic Hepatitis C Infection
KITE-363
Relapsed and/or Refractory B-cell Lymphoma
D/C/F/TAF
Acquired Immunodeficiency Syndrome
GS-9876
Rheumatoid Arthritis
Simtuzumab
Primary Sclerosing Cholangitis (PSC)
Tecadenoson
Atrial Fibrillation
Tegobuvir (GS-9190)
Hepatitis C, Chronic
OAV Regimen
Chronic HBV Infection
emvistegrast
Ulcerative Colitis
GS-9190
HCV Infection
GS-9450
Nonalcoholic Steatohepatitis
Ledipasvir
Hepatitis B
emtricitabine, FTC (drug)
HIV Infections
Hepatitis B Immunoglobulin (HBIg)
Chronic Hepatitis B
GS-5885
Hepatitis C, Chronic
90Y-hLL2
NHL
MBX-8025
Hyperlipidemia
Vesatolimod
HIV-1-infection
Antibody-Drug Conjugates
Advanced or Metastatic Solid Tumour
Arhalofenate
Hyperuricemia
Copegus®
Hepatitis C, Chronic
veltuzumab
NHL
GS-5885 tablet
Hepatitis C, Chronic
Abacavir
HIV
GS-9137 - A Novel HIV-1 Integrase Inhibitor
HIV
VAS
Nonalcoholic Steatohepatitis (NASH)
Inavolisib (Dose #2)
Metastatic Breast Cancer
Tecartus
B-Cell Lymphoblastic Leukemia
Entecavir (ETV)
Chronic Hepatitis B
Cilofexor Dose B
Primary Biliary Cholangitis
Chemotherapy (Gemcitabine + Carboplatin or Eribulin)
Metastatic Breast Cancer
Emtricitabine/Tenofovir Disoproxil Oral Tablet
Acceptability of Health Care
GS-9674
Nonalcoholic Steatohepatitis (NASH)
anitocabtagene-autoleucel
Multiple Myeloma
Selicrelumab
Metastatic Breast Cancer
Ribociclib (Dose #2)
Metastatic Breast Cancer
Atirmociclib
Metastatic Breast Cancer
TUB-030
Advanced Solid Tumors
KTE-X19
Relapsed/Refractory Mantle Cell Lymphoma
Ribociclib (Dose #1)
Metastatic Breast Cancer
Inavolisib (Dose #1)
Metastatic Breast Cancer
FENO
Nonalcoholic Steatohepatitis (NASH)
Presatovir
Respiratory Syncytial Virus
CILO
Nonalcoholic Steatohepatitis (NASH)
Pegasys®
Chronic Hepatitis C Infection
PSI-7977 (GS7977)
Hepatitis C
Amprenavir
HIV Infections
GS-5734
Ebola
VDV
Hepatitis C Virus Infection
Tirabrutinib
Chronic Lymphocytic Leukemia
FTI, AZLI
Cystic Fibrosis
Liposomal amphotericin B + miltefosine
Primary Visceral Leishmaniasis
EFV
Hepatitis C
milatuzumab
Chronic Lymphocytic Lymphoma
Emtricitabine
HIV Infections
MBX-8025 (Dose Escalation Period 1)
Homozygous Familial Hypercholesterolemia
Tegobuvir
Hepatitis C, Chronic
GS-4321
Chronic Hepatitis Delta
ribavirin tablet
Hepatitis C, Chronic
Brexucabtagene Autoleucel (KTE-X19)
Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia
Cidofovir
Cytomegalovirus Retinitis
hA20-humanized anti-CD20 antibody
Non-Hodgkin's Lymphoma
Febuxostat
Gout
TUB-040 + Carbo + BEV
Ovarian Cancer
GS-0938
Hepatitis C, Chronic
radiolabeled epratuzumab
Non-Hodgkin's Lymphoma
GS-1427
Ulcerative Colitis
Nelfinavir mesylate
HIV Infections
Entospletinib
Anemia
veltuzumab and milatuzumab
Lymphoma
Eleclazine
Ventricular Arrhythmia
High-dose methylprednisolone
Refractory Diffuse Large B Cell Lymphoma (DLBCL)
SEL
Diabetic Kidney Disease
Liposomal amphotericin B (AmBisome®) and sodium stibogluconate
Primary Visceral Leishmaniasis
Denikitug
HER2-negative
Adefovir dipivoxil and hepatitis B vaccination
Hepatitis B
Antiretroviral Therapy
HIV-1 Infection
Vaccine Group A: DNA-HIV-PT123 and AIDSVAX® B/E (weeks 0,4,24,48)
HIV Infections
Vaccine Group B: DNA-HIV-PT123 and CN54gp140+MPLA-L (weeks 0,4), then MVA and CN54gp140+MPLA-L (weeks 24,48)
HIV Infections
Experimental PrEP:TAF/FTC once daily (weeks 0-26)
HIV Infections
Cilofexor Dose A
Primary Biliary Cholangitis
GS-5806
Respiratory Syncytial Virus Infections
Cilofexor
Primary Sclerosing Cholangitis
Miltefosine
Primary Visceral Leishmaniasis
Selonsertib
Alcoholic Hepatitis (AH)
VEL
Hepatitis C
hMN14 (labetuzumab)
Pancreatic Neoplasms
Abacavir sulfate
HIV Infections
EVG
HIV Infections
Granulocyte Colony-Stimulating Factor
Triple Negative Breast Cancer
Lanraplenib
Lupus Membranous Nephropathy
GS-9669
Chronic HCV Infection
GS-9256
HCV Infection
MBX-2044
Type 2 Diabetes Mellitus
Selgantolimod
Chronic Hepatitis B
Indinavir sulfate
HIV Infections
Zimberelimab (ZIM)
Lung Cancer
90Y-hPAM4
Pancreatic Cancer
• TF2 and 68 Ga-IMP-288
Medullary Thyroid Carcinoma
Emtricitabine/tenofovir (FTC/TDF (Truvada®))
HIV Infection
TMC435
Hepatitis C
Switch to E/C/FTC/TAF daily
HIV/AIDS
Emtricitabine/tenofovir disoproxil fumarate (F/TDF)
Pre-Exposure Prophylaxis of HIV Infection
Epclusa
End Stage Renal Disease
PTM Cilofexor Dose A
Primary Biliary Cholangitis
PTM Cilofexor Dose B
Primary Biliary Cholangitis
IMMU-107 (hPAM4)
Pancreatic Cancer
Edecesertib
Cutaneous Lupus Erythematosus (CLE)
Hepatitis B virus (HBV) OAV Therapy
Chronic Hepatitis B
BSF 208075
Pulmonary Hypertension
VOX
Hepatitis C Virus Infection
tegobuvir capsule
Chronic Genotype 1a or 1b HCV Infection
Remdesivir (RDV)
COVID-19
TF2 - 68 Ga-IMP-288
HER2 Negative Breast Carcinoma Expressing CEA
Efavirenz
HIV Infections
VRC07523LS
HIV-1-infection
Sofosbuvir/Velpatasvir/Voxilaprevir
Chronic Hepatitis C
GS-3242
HIV-1 Infection
Cilofexor (CILO)/Firsocostat (FIR)
Nonalcoholic Steatohepatitis
CAP256V2LS
HIV-1-infection
Trastuzumab and Hyaluronidase-oysk
Her 2 Positive Breast Cancer
Trifluridine-Tipiracil
Advanced Microsatellite Stable Colorectal Cancer
Zydelig
Non Hodgkin Lymphoma
LDV/SOF FDC
Acute Hepatitis C
emtricitabine/tenofovir DF
Chronic Hepatitis B
Sofosbuvir and Velpatasvir
Hepatitis C
Probenecid
Cytomegalovirus Retinitis
Tenofovir disoproxil fumarate (tenofovir DF; TDF)
Chronic Hepatitis B
BIC
HIV-1 Infection
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Trodelvy Sacituzumab Govitecan | Approved | Triple-Negative Breast Cancer | Fast TrackBreakthrough | - |
MTX | Phase 3 | Rheumatoid Arthritis | - | - |
Sustiva (Efavirenz) | Phase 3 | HIV Infections | - | - |
abacavir + didanosine + lopinavir/ritonavir (WHO recommended second line) | Phase 3 | HIV | - | - |
Epivir (Lamivudine) | Phase 3 | HIV Infections | - | - |
Antiretroviral medications | Phase 3 | HIV Infections | - | - |
Antiretroviral medications+Isoniazid prophylaxis | Phase 3 | HIV Infections | - | - |
TAF/FTC/fixed-dose combination | Phase 3 | HIV/AIDS | - | - |
B/F/TAF (TOS) | Phase 3 | HIV-1 Infection | - | - |
B/F/TAF (Low Dose) | Phase 3 | HIV-1 Infection | - | - |
Zimberelimab | Phase 3 | Head and Neck Squamous Cell Carcinoma | - | - |
Stribild | Phase 3 | Acquired Immunodeficiency Syndrome | - | - |
Sacituzumab Govitecan (SG) | Phase 3 | Extensive Stage Small Cell Lung Cancer (ES-SCLC) | - | - |
Baseline DRV- containing ARV regimen | Phase 3 | HIV-1 | - | - |
RTV | Phase 3 | Acquired Immunodeficiency Syndrome | - | - |
Seladelpar | Phase 3 | Primary Biliary Cholangitis | - | - |
Current failing ARV regimen | Phase 3 | HIV | - | - |
Adefovir Dipivoxil (ADV) | Phase 3 | Chronic Hepatitis B | - | - |
ABC/DTG/3TC | Phase 3 | HIV-1 Infection | - | - |
Axicabtagene Ciloleucel | Phase 3 | High-risk Large B-cell Lymphoma (LBCL) | - | - |
ABC/3TC | Phase 3 | HIV-1 Infection | - | - |
Elvitegravir | Phase 3 | HIV Infection | - | - |
nebulised liposomal amphotericin B | Phase 3 | Aspergillosis | - | - |
GS-4182 | Phase 3 | HIV-1-Infection | - | - |
F/R/TAF | Phase 3 | HIV-1 Infection | - | - |
Stable Baseline Regimen | Phase 3 | HIV-1-infection | - | - |
Remdesivir | Phase 3 | COVID-19 | - | - |
Zidovudine | Phase 3 | HIV Infections | - | - |
Adefovir Dipivoxil for | Phase 3 | Chronic Hepatitis B | - | - |
Platinum-containing Salvage Chemotherapy | Phase 3 | Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | - | - |
Tobramycin inhalation solution | Phase 3 | Cystic Fibrosis | - | - |
Lenacapavir Tablet | Phase 3 | HIV Pre-exposure Prophylaxis | - | - |
F/TAF | Phase 3 | HIV-1 Infection | - | - |
EVG/COBI/FTC/TDF | Phase 3 | Acquired Immunodeficiency Syndrome | - | - |
EFV/FTC/TDF | Phase 3 | HIV | - | - |
Subcutaneous Lenacapavir | Phase 3 | HIV-1-infection | - | - |
NRTIs | Phase 3 | HIV-1 Infection | - | - |
TAF | Phase 3 | HBeAg-positive Chronic Hepatitis B | - | - |
Background regimen | Phase 3 | HIV Infection | - | - |
RBV | Phase 3 | Hepatitis C Virus Infection | - | - |
Atripla | Phase 3 | HIV | - | - |
Lepetegravir/Lenacapavir pacfosacil FDC | Phase 3 | HIV-1-Infection | - | - |
GS-3242 Injection | Phase 3 | HIV-1-infection | - | - |
COBI | Phase 3 | Acquired Immunodeficiency Syndrome | - | - |
Lepetegravir | Phase 3 | HIV-1-Infection | - | - |
Lenacapavir pacfosacil | Phase 3 | HIV-1-Infection | - | - |
Adenosine | Phase 3 | Coronary Artery Disease | - | - |
Tenofovir disoproxil fumarate | Phase 3 | Chronic Hepatitis B | - | - |
Boosted PIs | Phase 3 | HIV-1 | - | - |
Tobramycin Inhalation Solution (TIS) | Phase 3 | Cystic Fibrosis | - | - |
PEGASYS (Interféron pégylé alpha -2a) | Phase 3 | Hepatitis B | - | - |
PTM B/F/TAF | Phase 3 | HIV-1-infection | - | - |
B/F/TAF (Adult Strength) | Phase 3 | HIV-1 Infection | - | - |
FTC/RPV/TDF | Phase 3 | HIV-1 Infection | - | - |
E/C/F/TAF | Phase 3 | HIV | - | - |
Tenofovir disoproxil fumarate (TDF) | Phase 3 | Hepatitis B Virus (HBV) | - | - |
Teropavimab | Phase 3 | HIV Infection | - | - |
SOF | Phase 3 | Hepatitis C | - | - |
BIC/LEN FDC | Phase 3 | HIV-1-infection | - | - |
FTC/TDF | Phase 3 | Chronic Hepatitis B | - | - |
Oral Lenacapavir | Phase 3 | HIV-1-infection | - | - |
Ranolazine | Phase 3 | Type 2 Diabetes Mellitus | - | - |
AZLI | Phase 3 | Cystic Fibrosis | - | - |
Tenofovir DF | Phase 3 | HIV Infections | - | - |
B/F/TAF | Phase 3 | HIV-1-infection | - | - |
F/TDF | Phase 3 | Pre-Exposure Prophylaxis of HIV-1 Infection | - | - |
MBX-102 | Phase 3 | Type 2 Diabetes | - | - |
Filgotinib | Phase 3 | Ulcerative Colitis | - | - |
Aztreonam for Inhalation Solution (AZLI) | Phase 3 | Cystic Fibrosis | - | - |
Idelalisib | Phase 3 | Hodgkin Lymphoma | - | - |
SOF/VEL | Phase 3 | Hepatitis C Virus Infection | - | - |
Sacituzumab govitecan-hziy (SG) | Phase 3 | Triple Negative Breast Cancer | - | - |
Peg-IFN | Phase 3 | Hepatitis C | - | - |
Sacituzumab Govitecan-hziy | Phase 3 | Triple Negative Breast Cancer | - | - |
DRV/co | Phase 3 | HIV-1 Infection | - | - |
SBR | Phase 3 | HIV-1-infection | - | - |
csDMARDs | Phase 3 | Rheumatoid Arthritis | - | - |
ADV | Phase 3 | Chronic Hepatitis B | - | - |
Zinlirvimab | Phase 3 | HIV-1-infection | - | - |
Lenacapavir Injection | Phase 3 | Pre-Exposure Prophylaxis of HIV Infection | - | - |
Tenofovir Alafenamide | Phase 3 | Chronic Hepatitis B | - | - |
AmBisome | Phase 3 | Invasive Aspergillosis | - | - |
DTG | Phase 3 | HIV-1/HBV Co-Infection | - | - |
Anitocabtagene Autoleucel | Phase 3 | Multiple Myeloma | - | - |
Liposomal amphotericin B | Phase 3 | Invasive Fungal Disease | - | - |
ATV/co | Phase 3 | HIV-1 Infection | - | - |
Andecaliximab | Phase 3 | Gastric Adenocarcinoma | - | - |
Domvanalimab | Phase 3 | Advanced Non-Small Cell Lung Cancer | - | - |
Eribulin | Phase 3 | Metastatic Breast Cancer | - | - |
E/C/F/TDF | Phase 3 | HIV | - | - |
PI | Phase 3 | HIV-1 Infection | - | - |
TDF | Phase 3 | Chronic Hepatitis B | - | - |
LDV/SOF | Phase 3 | Chronic Hepatitis C Virus | - | - |
ambrisentan | Phase 3 | Pulmonary Hypertension | - | - |
Optimized Background Regimen (OBR) | Phase 3 | HIV-1-infection | - | - |
Eribulin Mesylate Injection | Phase 3 | Metastatic Breast Cancer | - | - |
Viread (tenofovir disoproxil fumarate) | Phase 3 | HIV Infections | - | - |
KITE-753 | Phase 3 | Relapsed or Refractory Large B-cell Lymphoma | - | - |
GS-1720 | Phase 3 | HIV-1-infection | - | - |
AZLI two times | Phase 3 | Cystic Fibrosis | - | - |
Cobicistat | Phase 3 | Acquired Immune Deficiency Syndrome (AIDS) | - | - |
SOF/VEL/VOX | Phase 3 | Hepatitis C Virus Infection | - | - |
NNRTI | Phase 3 | Acquired Immunodeficiency Syndrome | - | - |
Obeldesivir | Phase 3 | COVID-19 | - | - |
PEG | Phase 3 | Hepatitis C | - | - |
Bictegravir | Phase 3 | HIV-1-infection | - | - |
Sofosbuvir | Phase 3 | Hepatitis C, Chronic | - | - |
E/C/F/TAF (Low Dose) | Phase 3 | Acquired Immune Deficiency Syndrome (AIDS) | - | - |
ISL/LEN | Phase 3 | HIV-1-Infection | - | - |
Biktarvy | Phase 3 | Human Immunodeficiency Virus | - | - |
Ledipasvir/Sofosbuvir | Phase 3 | Hepatitis C, Chronic | - | - |
Bulevirtide | Phase 3 | Chronic Hepatitis Delta | - | - |
Darusentan | Phase 3 | Hypertension | - | - |
FTC | Phase 3 | Chronic Hepatitis B | - | - |
3rd ARV agent | Phase 3 | HIV-1 | - | - |
Emtricitabine (FTC) | Phase 3 | HIV Infections | - | - |
DRV | Phase 3 | HIV-1 Infection | - | - |
AZLI three times | Phase 3 | Cystic Fibrosis | - | - |
Regadenoson | Phase 3 | Coronary Artery Disease | - | - |
ATV | Phase 3 | HIV | - | - |
FTC/RPV/TAF | Phase 3 | HIV-1 Infection | - | - |
Vinflunine | Phase 3 | Locally Advanced or Metastatic Unresectable Urothelial Cancer | - | - |
3TC | Phase 3 | HIV-1 Infection | - | - |
zidovudine and lamivudine (Combivir®) | Phase 3 | HIV Infections | - | - |
Subcutaneous (SC) Lenacapavir (LEN) | Phase 3 | Pre-Exposure Prophylaxis of HIV Infection | - | - |
Failing ARV Regimen | Phase 3 | HIV-1-infection | - | - |
F/TAF (for US participants only) | Phase 3 | Pre-Exposure Prophylaxis of HIV Infection | - | - |
LPV/r | Phase 3 | Acquired Immune Deficiency Syndrome (AIDS) | - | - |
Oral Lenacapavir (LEN) | Phase 3 | Pre-Exposure Prophylaxis of HIV Infection | - | - |
Sub-cutaneous (SC) Lenacapavir (LEN) | Phase 3 | Pre-Exposure Prophylaxis of HIV Infection | - | - |
Third Unboosted Drug | Phase 3 | Acquired Immune Deficiency Syndrome (AIDS) | - | - |
Cobicistat TOS | Phase 3 | Acquired Immune Deficiency Syndrome (AIDS) | - | - |
F/TAF TOS | Phase 3 | Acquired Immune Deficiency Syndrome (AIDS) | - | - |
PTM F/TDF | Phase 3 | Pre-Exposure Prophylaxis of HIV Infection | - | - |
Ledipasvir-Sofosbuvir | Phase 3 | Human Immunodeficiency Virus | - | - |
PTM Oral LEN | Phase 3 | Pre-Exposure Prophylaxis of HIV Infection | - | - |
co-formulated TAF/FTC | Phase 3 | HIV Infections | - | - |
NRTI | Phase 3 | Acquired Immunodeficiency Syndrome | - | - |
GS-3242 Tablet | Phase 3 | HIV-1-infection | - | - |
Descovy or Truvada | Phase 3 | HIV Infections | - | - |
Harvoni | Phase 3 | Hepatitis C | - | - |
Tenofovir (TDF) | Phase 3 | HIV Infection | - | - |
emtricitabine and tenofovir DF | Phase 3 | HIV Infections | - | - |
raltegravir; maraviroc; darunavir; ritonavir; tenofovir/emtricitabine | Phase 3 | HIV-1 Infections | - | - |
enfuvirtide | Phase 3 | HIV Infections | - | - |
Sacituzumab Govitecan | Phase 3 | Breast Cancer | - | - |
Genvoya | Phase 3 | HIV Risk | - | - |
PTM ISL/LEN | Phase 3 | HIV-1-infection | - | - |
Single dose liposomal Amphotericin and Fluconazole | Phase 3 | Cryptococcal Meningitis | - | - |
Emtricitabine/tenofovir disoproxil fumarate | Phase 3 | HIV Infection | - | - |
Truvada | Phase 3 | HIV Infections | - | - |
Symtuza | Phase 3 | HIV/AIDS | - | - |
Aviptadil | Phase 3 | Covid19 | - | - |
Bictegravir/Lenacapavir (BIC/LEN) FDC | Phase 3 | HIV-1-infection | - | - |
Corticosteroid | Phase 3 | Covid19 | - | - |
Amrubicin (Japan only) | Phase 3 | Extensive Stage Small Cell Lung Cancer (ES-SCLC) | - | - |
Bictegravir/Lenacapavir | Phase 3 | HIV-1-infection | - | - |
Deferred Intervention Arm | Phase 3 | HIV Prevention | - | - |
Lurbinectedin (regions/countries where approved and available) | Phase 3 | Extensive Stage Small Cell Lung Cancer (ES-SCLC) | - | - |
Immediate Intervention Arm | Phase 3 | HIV Prevention | - | - |
Darunavir | Phase 3 | HIV Infection | - | - |
Efavirenz (EFV) | Phase 3 | HIV Infections | - | - |
FTC/TDF/EFV | Phase 3 | HIV Infections | - | - |
Rilpivirine/Emtricitabine/Tenofovir | Phase 3 | HIV | - | - |
Atazanavir | Phase 3 | HIV Infection | - | - |
Lenacapavir | Phase 3 | HIV Prevention | Fast TrackBreakthrough | Patent 2041 |
Magrolimab | Phase 3 | Myelodysplastic Syndrome | OrphanFast TrackBreakthrough | - |
didanosine, ddI (drug) | Phase 3 | HIV Infections | - | - |
efavirenz (drug) | Phase 3 | HIV Infections | - | - |
Cabotegravir Oral Tablet | Phase 3 | HIV Infections | - | - |
CAB LA | Phase 3 | HIV Infections | - | - |
Tenofovir Disoproxil Fumarate + Emtricitabine | Phase 3 | HIV Infections | - | - |
TDF/FTC tablets | Phase 3 | HIV Infections | - | - |
emtricitabine/tenofovir + lopinavir/ritonavir (WHO recommended second line) | Phase 3 | HIV | - | - |
emtricitabine/tenofovir + darunavir + ritonavir (Second line strategy under evaluation) | Phase 3 | HIV | - | - |
FIR | Phase 2 | Nonalcoholic Steatohepatitis | - | - |
Adefovir Dipivoxil | Phase 2 | Hepatitis B | - | - |
ISL | Phase 2 | HIV-1 Infection | - | - |
GS-9451 | Phase 2 | Hepatitis C, Chronic | - | - |
KTE-C19 | Phase 2 | Refractory Diffuse Large B Cell Lymphoma | - | - |
brexucabtagene autoleucel | Phase 2 | Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia | - | - |
emtricitabine/tenofovir alafenamide | Phase 2 | Acceptability of Health Care | - | - |
Quemliclustat | Phase 2 | Biliary Tract Carcinoma | - | - |
Emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) | Phase 2 | Chronic Hepatitis B | - | - |
SIM | Phase 2 | Non-Alcoholic Steatohepatitis (NASH) | - | - |
Esmolol | Phase 2 | Atrial Fibrillation | - | - |
GS-9451 tablet | Phase 2 | Chronic Genotype 1a or 1b HCV Infection | - | - |
MVA.HTI | Phase 2 | HIV/AIDS | - | - |
Sacituzumab Govitecan-Hziy plus bevacizumab | Phase 2 | NSCLC Stage IV | - | - |
Levocarnitine | Phase 2 | HIV Infections | - | - |
ChAdOx1.HTI | Phase 2 | HIV/AIDS | - | - |
GS-9620 | Phase 2 | HIV/AIDS | - | - |
Aztreonam for Inhalation (AI) | Phase 2 | Cystic Fibrosis | - | - |
Tilpisertib Fosmecarbil | Phase 2 | Ulcerative Colitis | - | - |
Therapeutic Hydrocortisone | Phase 2 | Non-hodgkin Lymphoma | - | - |
Etrumadenant | Phase 2 | Metastatic Colorectal Cancer | - | - |
Dronedarone | Phase 2 | Atrial Fibrillation | - | - |
Axi-cel | Phase 2 | B Cell Lymphoma | - | - |
MBX-2982 | Phase 2 | Diabetes | - | - |
Other approved antivirals | Phase 2 | Chronic Hepatitis B | - | - |
Firsocostat | Phase 2 | Nonalcoholic Steatohepatitis (NASH) | - | - |
PTM CILO/FIR | Phase 2 | Nonalcoholic Steatohepatitis | - | - |
PTM SEMA | Phase 2 | Nonalcoholic Steatohepatitis | - | - |
ZDV/3TC | Phase 2 | Hepatitis C | - | - |
RAL | Phase 2 | Hepatitis C | - | - |
Levetiracetam | Phase 2 | Refractory Diffuse Large B Cell Lymphoma (DLBCL) | - | - |
Peginterferon Alfa 2a | Phase 2 | HCV Infection | - | - |
TUB-040 | Phase 2 | Ovarian Cancer | - | - |
LDV | Phase 2 | Chronic Hepatitis C Infection | - | - |
KITE-363 | Phase 2 | Relapsed and/or Refractory B-cell Lymphoma | - | - |
D/C/F/TAF | Phase 2 | Acquired Immunodeficiency Syndrome | - | - |
GS-9876 | Phase 2 | Rheumatoid Arthritis | - | - |
Simtuzumab | Phase 2 | Primary Sclerosing Cholangitis (PSC) | - | - |
Tecadenoson | Phase 2 | Atrial Fibrillation | - | - |
Tegobuvir (GS-9190) | Phase 2 | Hepatitis C, Chronic | - | - |
OAV Regimen | Phase 2 | Chronic HBV Infection | - | - |
emvistegrast | Phase 2 | Ulcerative Colitis | - | - |
GS-9190 | Phase 2 | HCV Infection | - | - |
GS-9450 | Phase 2 | Nonalcoholic Steatohepatitis | - | - |
Ledipasvir | Phase 2 | Hepatitis B | - | - |
emtricitabine, FTC (drug) | Phase 2 | HIV Infections | - | - |
Hepatitis B Immunoglobulin (HBIg) | Phase 2 | Chronic Hepatitis B | - | - |
GS-5885 | Phase 2 | Hepatitis C, Chronic | - | - |
90Y-hLL2 | Phase 2 | NHL | - | - |
MBX-8025 | Phase 2 | Hyperlipidemia | - | - |
Vesatolimod | Phase 2 | HIV-1-infection | - | - |
Antibody-Drug Conjugates | Phase 2 | Advanced or Metastatic Solid Tumour | - | - |
Arhalofenate | Phase 2 | Hyperuricemia | - | - |
Copegus® | Phase 2 | Hepatitis C, Chronic | - | - |
veltuzumab | Phase 2 | NHL | - | - |
GS-5885 tablet | Phase 2 | Hepatitis C, Chronic | - | - |
Abacavir | Phase 2 | HIV | - | - |
GS-9137 - A Novel HIV-1 Integrase Inhibitor | Phase 2 | HIV | - | - |
VAS | Phase 2 | Nonalcoholic Steatohepatitis (NASH) | - | - |
Inavolisib (Dose #2) | Phase 2 | Metastatic Breast Cancer | - | - |
Tecartus | Phase 2 | B-Cell Lymphoblastic Leukemia | - | - |
Entecavir (ETV) | Phase 2 | Chronic Hepatitis B | - | - |
Cilofexor Dose B | Phase 2 | Primary Biliary Cholangitis | - | - |
Chemotherapy (Gemcitabine + Carboplatin or Eribulin) | Phase 2 | Metastatic Breast Cancer | - | - |
Emtricitabine/Tenofovir Disoproxil Oral Tablet | Phase 2 | Acceptability of Health Care | - | - |
GS-9674 | Phase 2 | Nonalcoholic Steatohepatitis (NASH) | - | - |
anitocabtagene-autoleucel | Phase 2 | Multiple Myeloma | - | - |
Selicrelumab | Phase 2 | Metastatic Breast Cancer | - | - |
Ribociclib (Dose #2) | Phase 2 | Metastatic Breast Cancer | - | - |
Atirmociclib | Phase 2 | Metastatic Breast Cancer | - | - |
TUB-030 | Phase 2 | Advanced Solid Tumors | - | - |
KTE-X19 | Phase 2 | Relapsed/Refractory Mantle Cell Lymphoma | - | - |
Ribociclib (Dose #1) | Phase 2 | Metastatic Breast Cancer | - | - |
Inavolisib (Dose #1) | Phase 2 | Metastatic Breast Cancer | - | - |
FENO | Phase 2 | Nonalcoholic Steatohepatitis (NASH) | - | - |
Presatovir | Phase 2 | Respiratory Syncytial Virus | - | - |
CILO | Phase 2 | Nonalcoholic Steatohepatitis (NASH) | - | - |
Pegasys® | Phase 2 | Chronic Hepatitis C Infection | - | - |
PSI-7977 (GS7977) | Phase 2 | Hepatitis C | - | - |
Amprenavir | Phase 2 | HIV Infections | - | - |
GS-5734 | Phase 2 | Ebola | - | - |
VDV | Phase 2 | Hepatitis C Virus Infection | - | - |
Tirabrutinib | Phase 2 | Chronic Lymphocytic Leukemia | - | - |
FTI, AZLI | Phase 2 | Cystic Fibrosis | - | - |
Liposomal amphotericin B + miltefosine | Phase 2 | Primary Visceral Leishmaniasis | - | - |
EFV | Phase 2 | Hepatitis C | - | - |
milatuzumab | Phase 2 | Chronic Lymphocytic Lymphoma | - | - |
Emtricitabine | Phase 2 | HIV Infections | - | - |
MBX-8025 (Dose Escalation Period 1) | Phase 2 | Homozygous Familial Hypercholesterolemia | - | - |
Tegobuvir | Phase 2 | Hepatitis C, Chronic | - | - |
GS-4321 | Phase 2 | Chronic Hepatitis Delta | - | - |
ribavirin tablet | Phase 2 | Hepatitis C, Chronic | - | - |
Brexucabtagene Autoleucel (KTE-X19) | Phase 2 | Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia | - | - |
Cidofovir | Phase 2 | Cytomegalovirus Retinitis | - | - |
hA20-humanized anti-CD20 antibody | Phase 2 | Non-Hodgkin's Lymphoma | - | - |
Febuxostat | Phase 2 | Gout | - | - |
TUB-040 + Carbo + BEV | Phase 2 | Ovarian Cancer | - | - |
GS-0938 | Phase 2 | Hepatitis C, Chronic | - | - |
radiolabeled epratuzumab | Phase 2 | Non-Hodgkin's Lymphoma | - | - |
GS-1427 | Phase 2 | Ulcerative Colitis | - | - |
Nelfinavir mesylate | Phase 2 | HIV Infections | - | - |
Entospletinib | Phase 2 | Anemia | - | - |
veltuzumab and milatuzumab | Phase 2 | Lymphoma | - | - |
Eleclazine | Phase 2 | Ventricular Arrhythmia | - | - |
High-dose methylprednisolone | Phase 2 | Refractory Diffuse Large B Cell Lymphoma (DLBCL) | - | - |
SEL | Phase 2 | Diabetic Kidney Disease | - | - |
Liposomal amphotericin B (AmBisome®) and sodium stibogluconate | Phase 2 | Primary Visceral Leishmaniasis | - | - |
Denikitug | Phase 2 | HER2-negative | - | - |
Adefovir dipivoxil and hepatitis B vaccination | Phase 2 | Hepatitis B | - | - |
Antiretroviral Therapy | Phase 2 | HIV-1 Infection | - | - |
Vaccine Group A: DNA-HIV-PT123 and AIDSVAX® B/E (weeks 0,4,24,48) | Phase 2 | HIV Infections | - | - |
Vaccine Group B: DNA-HIV-PT123 and CN54gp140+MPLA-L (weeks 0,4), then MVA and CN54gp140+MPLA-L (weeks 24,48) | Phase 2 | HIV Infections | - | - |
Experimental PrEP:TAF/FTC once daily (weeks 0-26) | Phase 2 | HIV Infections | - | - |
Cilofexor Dose A | Phase 2 | Primary Biliary Cholangitis | - | - |
GS-5806 | Phase 2 | Respiratory Syncytial Virus Infections | - | - |
Cilofexor | Phase 2 | Primary Sclerosing Cholangitis | - | - |
Miltefosine | Phase 2 | Primary Visceral Leishmaniasis | - | - |
Selonsertib | Phase 2 | Alcoholic Hepatitis (AH) | - | - |
VEL | Phase 2 | Hepatitis C | - | - |
hMN14 (labetuzumab) | Phase 2 | Pancreatic Neoplasms | - | - |
Abacavir sulfate | Phase 2 | HIV Infections | - | - |
EVG | Phase 2 | HIV Infections | - | - |
Granulocyte Colony-Stimulating Factor | Phase 2 | Triple Negative Breast Cancer | - | - |
Lanraplenib | Phase 2 | Lupus Membranous Nephropathy | - | - |
GS-9669 | Phase 2 | Chronic HCV Infection | - | - |
GS-9256 | Phase 2 | HCV Infection | - | - |
MBX-2044 | Phase 2 | Type 2 Diabetes Mellitus | - | - |
Selgantolimod | Phase 2 | Chronic Hepatitis B | - | - |
Indinavir sulfate | Phase 2 | HIV Infections | - | - |
Zimberelimab (ZIM) | Phase 2 | Lung Cancer | - | - |
90Y-hPAM4 | Phase 2 | Pancreatic Cancer | - | - |
• TF2 and 68 Ga-IMP-288 | Phase 2 | Medullary Thyroid Carcinoma | - | - |
Emtricitabine/tenofovir (FTC/TDF (Truvada®)) | Phase 2 | HIV Infection | - | - |
TMC435 | Phase 2 | Hepatitis C | - | - |
Switch to E/C/FTC/TAF daily | Phase 2 | HIV/AIDS | - | - |
Emtricitabine/tenofovir disoproxil fumarate (F/TDF) | Phase 2 | Pre-Exposure Prophylaxis of HIV Infection | - | - |
Epclusa | Phase 2 | End Stage Renal Disease | - | - |
PTM Cilofexor Dose A | Phase 2 | Primary Biliary Cholangitis | - | - |
PTM Cilofexor Dose B | Phase 2 | Primary Biliary Cholangitis | - | - |
IMMU-107 (hPAM4) | Phase 2 | Pancreatic Cancer | - | - |
Edecesertib | Phase 2 | Cutaneous Lupus Erythematosus (CLE) | - | - |
Hepatitis B virus (HBV) OAV Therapy | Phase 2 | Chronic Hepatitis B | - | - |
BSF 208075 | Phase 2 | Pulmonary Hypertension | - | - |
VOX | Phase 2 | Hepatitis C Virus Infection | - | - |
tegobuvir capsule | Phase 2 | Chronic Genotype 1a or 1b HCV Infection | - | - |
Remdesivir (RDV) | Phase 2 | COVID-19 | - | - |
TF2 - 68 Ga-IMP-288 | Phase 2 | HER2 Negative Breast Carcinoma Expressing CEA | - | - |
Efavirenz | Phase 2 | HIV Infections | - | - |
VRC07523LS | Phase 2 | HIV-1-infection | - | - |
Sofosbuvir/Velpatasvir/Voxilaprevir | Phase 2 | Chronic Hepatitis C | - | - |
GS-3242 | Phase 2 | HIV-1 Infection | - | - |
Cilofexor (CILO)/Firsocostat (FIR) | Phase 2 | Nonalcoholic Steatohepatitis | - | - |
CAP256V2LS | Phase 2 | HIV-1-infection | - | - |
Trastuzumab and Hyaluronidase-oysk | Phase 2 | Her 2 Positive Breast Cancer | - | - |
Trifluridine-Tipiracil | Phase 2 | Advanced Microsatellite Stable Colorectal Cancer | - | - |
Zydelig | Phase 2 | Non Hodgkin Lymphoma | - | - |
LDV/SOF FDC | Phase 2 | Acute Hepatitis C | - | - |
emtricitabine/tenofovir DF | Phase 2 | Chronic Hepatitis B | - | - |
Sofosbuvir and Velpatasvir | Phase 2 | Hepatitis C | - | - |
Probenecid | Phase 2 | Cytomegalovirus Retinitis | - | - |
Tenofovir disoproxil fumarate (tenofovir DF; TDF) | Phase 2 | Chronic Hepatitis B | - | - |
BIC | Phase 2 | HIV-1 Infection | - | - |
HIV
4 drugs in this indication
HIV Infections
2 drugs in this indication
Triple-Negative Breast Cancer
1 drug in this indication
HIV Prevention
1 drug in this indication
HIV-1
1 drug in this indication
Myelodysplastic Syndrome
1 drug in this indication
Rheumatoid Arthritis
1 drug in this indication
Hepatitis C, Chronic
1 drug in this indication
Refractory Diffuse Large B Cell Lymphoma
1 drug in this indication
CAR-T cell therapy
1 drug in this indication
HIV prevention (PrEP)
1 drug in this indication
PrEP (pre-exposure prophylaxis)
1 drug in this indication
HIV pre-exposure prophylaxis (PrEP)
1 drug in this indication
Biliary Tract Carcinoma
1 drug in this indication
first-line metastatic triple-negative breast cancer
1 drug in this indication
inflammatory bowel disease
1 drug in this indication
inflammation
1 drug in this indication
Previously untreated metastatic triple-negative breast cancer (mTNBC)
1 drug in this indication
primary biliary cholangitis (PBC)
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Gilead Sciences, Inc.'s drug pipeline?→
CatalystAlert tracks 337 drug candidates in Gilead Sciences, Inc.'s (GILD) pipeline across Phase 3, Phase 2, Approved. Its lead program is Lenacapavir (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Gilead Sciences, Inc.'s next FDA catalyst?→
Gilead Sciences, Inc.'s (GILD) next tracked catalyst is a PDUFA date expected Feb 2, 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track GILD biotech catalysts?→
Add GILD to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Gilead Sciences, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.
